TD Cowen Has Lowered Expectations for Danaher (NYSE:DHR) Stock Price

Danaher (NYSE:DHR) had its target price decreased by stock analysts at TD Cowen from $245.00 to $240.00 in a report released on Wednesday,MarketScreener reports. The firm currently has a “buy” rating on the conglomerate’s stock. TD Cowen’s target price points to a potential upside of 25.69% from the company’s current price.

Other research analysts have also recently issued reports about the company. Robert W. Baird reduced their price objective on Danaher from $251.00 to $249.00 and set an “outperform” rating on the stock in a research note on Friday. Guggenheim reduced their price objective on Danaher from $275.00 to $235.00 and set a “buy” rating on the stock in a research note on Wednesday. Wolfe Research cut their target price on Danaher from $260.00 to $230.00 and set an “outperform” rating on the stock in a research note on Wednesday, April 8th. JPMorgan Chase & Co. raised their target price on Danaher from $270.00 to $275.00 and gave the stock an “overweight” rating in a research note on Thursday, January 29th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $245.00 target price on shares of Danaher in a research note on Tuesday. Eighteen analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $241.95.

Danaher Stock Down 1.8%

Shares of NYSE:DHR opened at $190.95 on Wednesday. The stock’s 50-day moving average price is $197.89 and its 200-day moving average price is $214.56. Danaher has a 12-month low of $180.03 and a 12-month high of $242.80. The stock has a market capitalization of $135.13 billion, a P/E ratio of 37.89, a price-to-earnings-growth ratio of 2.66 and a beta of 0.95. The company has a current ratio of 1.87, a quick ratio of 1.51 and a debt-to-equity ratio of 0.35.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Tuesday, April 21st. The conglomerate reported $2.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.94 by $0.12. Danaher had a return on equity of 10.81% and a net margin of 14.71%.The firm had revenue of $5.95 billion for the quarter, compared to analysts’ expectations of $6 billion. During the same period last year, the firm earned $1.88 earnings per share. The company’s revenue for the quarter was up 3.7% compared to the same quarter last year. Danaher has set its FY 2026 guidance at 8.350-8.550 EPS. On average, equities analysts anticipate that Danaher will post 8.4 earnings per share for the current year.

Insider Buying and Selling

In other Danaher news, EVP Gregory M. Milosevich sold 1,320 shares of the firm’s stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $208.01, for a total value of $274,573.20. Following the completion of the sale, the executive vice president directly owned 5,099 shares in the company, valued at $1,060,642.99. This trade represents a 20.56% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. 10.80% of the stock is owned by company insiders.

Institutional Trading of Danaher

Several institutional investors and hedge funds have recently bought and sold shares of DHR. JPL Wealth Management LLC purchased a new stake in Danaher in the third quarter worth about $25,000. Elevated Capital Advisors LLC purchased a new position in shares of Danaher during the fourth quarter valued at approximately $26,000. WFA of San Diego LLC purchased a new position in shares of Danaher during the second quarter valued at approximately $26,000. ANTIPODES PARTNERS Ltd purchased a new position in shares of Danaher during the third quarter valued at approximately $27,000. Finally, Hilton Head Capital Partners LLC purchased a new position in shares of Danaher during the fourth quarter valued at approximately $27,000. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Danaher

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Q1 EPS beat and guidance lift — Danaher reported $2.06 EPS (above consensus) and raised FY26 EPS guidance to $8.35–8.55, signaling confidence in biotech and life‑sciences momentum; this is the main bullish driver. Danaher beats first-quarter profit estimates on strong bioprocessing demand
• Positive Sentiment: Bioprocessing and life‑sciences strength — management highlighted double‑digit momentum in bioprocessing and continued strength in life‑sciences tools, which should support margin expansion and cash generation. Danaher Lifts Full-Year Forecast on Biotech, Life Sciences Gains
• Neutral Sentiment: Investor materials and transcripts available — the company posted a press release, slide deck and a full earnings‑call transcript; useful for modeling segment trends and the acquisition roadmap but no immediate surprise. View Press Release / Slide Deck
• Neutral Sentiment: Strategic M&A focus — coverage notes Danaher’s acquisition strategy (including the Masimo-related work) as an important growth lever; strategic but timing and integration risk remain to be tracked. DHR Q1 deep dive: Bioprocessing momentum and acquisition strategy drive mixed start to 2026
• Negative Sentiment: Revenue slightly missed estimates — Q1 revenue was $5.95B vs. ~ $6.0B consensus, and that shortfall was cited as a reason for near‑term share weakness. Danaher (NYSE:DHR) Misses Q1 CY2026 Revenue Estimates
• Negative Sentiment: Diagnostics and respiratory softness — multiple reports flagged weakness in diagnostics and a lowered respiratory outlook, which could pressure near‑term organic growth until end markets recover. Danaher Q1 Earnings Beat Estimates, But Revenue Miss, Weak Diagnostics Weigh On Stock

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.